Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: A SEER-based analysis
- PMID: 31579519
- PMCID: PMC6760339
- DOI: 10.1093/nop/npv016
Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: A SEER-based analysis
Abstract
Background: The survival trends and the patterns of clinical practice pertaining to radiation therapy and surgical resection for WHO grade I, II, and III astrocytoma patients remain poorly characterized.
Methods: Using the Surveillance, Epidemiology and End Results (SEER) database, we identified 2497 grade I, 4113 grade II, and 2755 grade III astrocytomas during the period of 1999-2010. Time-trend analyses were performed for overall survival, radiation treatment (RT), and the extent of surgical resection (EOR).
Results: While overall survival of grade I astrocytoma patients remained unchanged during the study period, we observed improved overall survival for grade II and III astrocytoma patients (Tarone-Ware P < .05). The median survival increased from 44 to 57 months and from 15 to 24 months for grade II and III astrocytoma patients, respectively. The differences in survival remained significant after adjusting for pertinent variables including age, ethnicity, marital status, sex, tumor size, tumor location, EOR, and RT status. The pattern of clinical practice in terms of EOR for grade II and III astrocytoma patients did not change significantly during this study period. However, there was decreased RT utilization as treatment for grade II astrocytoma patients after 2005.
Conclusion: Results from the SEER database indicate that there were improvements in the overall survival of grade II and III astrocytoma patients over the past decade. Analysis of the clinical practice patterns identified potential opportunities for impacting the clinical course of these patients.
Keywords: WHO grade I, II, III astrocytomas; population-based SEER database; practice pattern; survival.
© The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Figures


Similar articles
-
Survival trends of oligodendroglial tumor patients and associated clinical practice patterns: a SEER-based analysis.J Neurooncol. 2017 May;133(1):173-181. doi: 10.1007/s11060-017-2430-z. Epub 2017 Apr 24. J Neurooncol. 2017. PMID: 28439777 Review.
-
Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis.J Neurosurg. 2018 Apr;128(4):1076-1083. doi: 10.3171/2016.11.JNS161974. Epub 2017 May 12. J Neurosurg. 2018. PMID: 28498059
-
Impact of the extent of resection on the survival of patients with grade II and III gliomas using awake brain mapping.J Neurooncol. 2021 Jun;153(2):361-372. doi: 10.1007/s11060-021-03776-w. Epub 2021 May 19. J Neurooncol. 2021. PMID: 34009509
-
Effect of Gross Total Resection in World Health Organization Grade II Astrocytomas: SEER-Based Survival Analysis.World Neurosurg. 2017 Jul;103:741-747. doi: 10.1016/j.wneu.2017.03.140. Epub 2017 Apr 16. World Neurosurg. 2017. PMID: 28419878
-
Surgical outcomes of pediatric spinal cord astrocytomas: systematic review and meta-analysis.J Neurosurg Pediatr. 2018 Oct;22(4):404-410. doi: 10.3171/2018.4.PEDS17587. Epub 2018 Jul 20. J Neurosurg Pediatr. 2018. PMID: 30028275
Cited by
-
Neurosurgical patterns of care for diffuse low-grade gliomas in Sweden between 2005 and 2015.Neurooncol Pract. 2019 Mar;6(2):124-133. doi: 10.1093/nop/npy023. Epub 2018 Jul 17. Neurooncol Pract. 2019. PMID: 30949360 Free PMC article.
-
Toxicological insights and safety considerations of vorasidenib in grade 2 astrocytoma and oligodendroglioma.Int J Surg. 2025 May 1;111(5):3685-3693. doi: 10.1097/JS9.0000000000002356. Int J Surg. 2025. PMID: 40171567 Free PMC article.
-
Comparable long term psychosocial burden in patients with lower grade versus higher grade brain tumors.Sci Rep. 2025 Jul 18;15(1):26089. doi: 10.1038/s41598-025-11456-2. Sci Rep. 2025. PMID: 40681619 Free PMC article.
-
5-aminolevulinic acid photodynamic therapy for the treatment of high-grade gliomas.J Neurooncol. 2019 Feb;141(3):595-607. doi: 10.1007/s11060-019-03103-4. Epub 2019 Jan 18. J Neurooncol. 2019. PMID: 30659522 Free PMC article. Review.
-
Novel treatments in optic pathway gliomas.Front Ophthalmol (Lausanne). 2022 Sep 29;2:992673. doi: 10.3389/fopht.2022.992673. eCollection 2022. Front Ophthalmol (Lausanne). 2022. PMID: 38983553 Free PMC article. Review.
References
-
- Bartek J Jr., Ng K, Bartek J et al. . Key concepts in glioblastoma therapy. J Neurol Neurosurg Psychiatry. 2012;83(7):753–760. - PubMed
-
- Ng K, Kim R, Kesari S et al. . Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights. J Neurooncol. 2012;107(1):1–12. - PubMed
-
- Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109(1):93–108. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous